| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary target of Inosine-5'-diphosphate disodium is NM23-H2 (also known as NME2). It exhibits excellent binding ability at the GDP-binding site of NM23-H2 with a dissociation constant (KD) of 5.0 microM. By disrupting the interaction between NM23-H2 and the c‑MYC G-quadruplex (Pu27‑GQ), it inhibits c-MYC transcription, leading to apoptosis and G2/M cell cycle arrest without affecting the kinase activity of NM23-H2.
|
|---|---|
| ln Vitro |
Inosine-5'-diphosphate disodium interferes with the interaction between NM23-H2 and c-MYC G-quadruplex (Pu27-GQ). Inosine-5'-diphosphate disodium binds to the guanosine diphosphate binding site of NM23-H2 (Kd = 5.0 μM). Inosine-5'-diphosphate disodium enhances the c-MYC transcriptional repression of the Pu27-GQ binding ligand. Inosine-5'-diphosphate disodium has anti-hypoxia, anti-hyperthermia, and anti-arrhythmic activities and can protect animals from the harmful effects of γ-ray irradiation. Inosine-5'-diphosphate disodium can be used for research on cancers such as Burkitt lymphoma and cardiovascular diseases [1][2][3].
In vitro, Inosine-5'-diphosphate disodium (IDP disodium) interferes with the interaction between NM23-H2 and the c‑MYC G-quadruplex (Pu27‑GQ). It binds to the NM23-H2 GDP-binding site (Kd = 5.0 microM) and enhances the inhibitory effect of Pu27‑GQ ligands on c‑MYC transcription. This activity induces cell apoptosis and G2/M phase cycle arrest without affecting the intrinsic kinase activity of NM23‑H2. The compound also exhibits anti-hypoxia, anti-hyperthermia, and anti-arrhythmia activities. |
| ln Vivo |
In vivo, Inosine-5'-diphosphate disodium has anti-hypoxic, anti-hyperthermic, and anti-arrhythmic activity and protects animals against the noxious effects of gamma-irradiation. It has important application value in the related research of malignant tumors such as Burkitt's lymphoma and cardiovascular diseases.
|
| Enzyme Assay |
Non-cell-based (cell-free) biochemical assays are used to study the binding interaction between IDP disodium and NM23-H2. Typically, purified recombinant NM23-H2 protein is incubated with increasing concentrations of IDP (0.1-50 microM) in a reaction buffer containing Tris-HCl (pH 7.4), MgCl2, and KCl. The binding affinity (KD = 5.0 microM) is determined using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). The competition for the GDP-binding site can be assessed by adding a fluorescently labeled GDP analog, and the displacement is measured by fluorescence polarization. The effect on c-MYC transcription is studied in a cell-free transcription assay using purified NM23-H2, c-MYC promoter DNA, and a G-quadruplex ligand.
|
| Cell Assay |
Cell-based experiments for Inosine-5'-diphosphate disodium are conducted using Burkitt's lymphoma cells. Cells are seeded in 6-well or 96-well plates and treated with increasing concentrations of IDP (0.1-50 microM) for 24-72 hours. Apoptosis is measured using flow cytometry with Annexin V/PI staining. Cell cycle progression is analyzed by flow cytometry after propidium iodide (PI) staining to detect the G2/M phase arrest. c-MYC transcription levels are measured by RT‑qPCR. The compound is typically dissolved in sterile water or DMSO, with a final concentration of DMSO <0.1% to avoid cytotoxicity.
|
| Animal Protocol |
In vivo animal experiments for Inosine-5'-diphosphate disodium are conducted in rodent models of radiation damage. Mice or rats are pretreated with IDP disodium (typically 10-50 mg/kg, intraperitoneally or intravenously) prior to exposure to a lethal dose of gamma-radiation (e.g., 7-9 Gy). The survival rate, body weight, and blood parameters (e.g., white blood cell count) are monitored over 30 days. The compound's protective effects against gamma-rays are assessed by comparing survival and recovery in treated vs. control groups. It is also tested in cardiovascular disease models, such as arrhythmia induced by ischemic-reperfusion, to evaluate its anti-arrhythmic effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Inosine-5'-diphosphate disodium are limited. As a nucleotide analog, it is likely to be rapidly dephosphorylated in the bloodstream to inosine monophosphate (IMP) and inosine. The compound is soluble in water (~175 mg/mL). It is stored as a powder at -20degC (stable for 3 years) or in a solvent at -80degC (stable for 6 months). The compound has a HS Tariff Code of 2934.99.9001.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Inosine-5'-diphosphate disodium is low. It is classified as a research compound and is not for human use. No significant adverse effects are reported at typical in vitro or in vivo research dosages. As a nucleotide, it is considered a relatively safe chemical. Standard safety precautions apply: avoid inhalation, ingestion, and contact with skin and eyes. It should be handled in a well-ventilated area with appropriate PPE.
|
| References | |
| Additional Infomation |
Additional information: The compound has a molecular formula of C10H14N4O11P2 (free acid) and a molecular weight of 428.19 g/mol. The disodium salt (C10H12N4Na2O11P2) has a molecular weight of 472.15. The CAS number is 54735-61-4. It is a white to off-white solid powder. Synonyms include 5'-inosine diphosphate disodium, IDP disodium, and Inosine-5'-diphosphoric acid disodium. The compound's purity is typically ≥99.93%.
|
| Molecular Formula |
C10H14N4O11P2
|
|---|---|
| Molecular Weight |
428.19
|
| Exact Mass |
471.977
|
| CAS # |
54735-61-4
|
| Related CAS # |
Inosine-5'-diphosphate-15N4 dilithium; Inosine-5'-diphosphate
|
| PubChem CID |
135742688
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
705
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)(O)[O-])O)O.[Na+].[Na+]
|
| InChi Key |
MYSOKTVZCUBKOZ-IDIVVRGQSA-L
|
| InChi Code |
InChI=1S/C10H14N4O11P2.2Na/c15-6-4(1-23-27(21,22)25-26(18,19)20)24-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;;/h2-4,6-7,10,15-16H,1H2,(H,21,22)(H,11,12,17)(H2,18,19,20);;/q;2*+1/p-2/t4-,6-,7-,10-;;/m1../s1
|
| Chemical Name |
disodium;[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl] hydrogen phosphate
|
| Synonyms |
5'-inosine diphosphate disodium; IDP disodium; Inosine-5'-diphosphoric acid disodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~175 mg/mL (~408.70 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3354 mL | 11.6771 mL | 23.3541 mL | |
| 5 mM | 0.4671 mL | 2.3354 mL | 4.6708 mL | |
| 10 mM | 0.2335 mL | 1.1677 mL | 2.3354 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
